SK12782001A3 - Protilátkové a chemokínové konštrukty a ich použitie pri liečbe autoimunitných chorôb - Google Patents
Protilátkové a chemokínové konštrukty a ich použitie pri liečbe autoimunitných chorôb Download PDFInfo
- Publication number
- SK12782001A3 SK12782001A3 SK1278-2001A SK12782001A SK12782001A3 SK 12782001 A3 SK12782001 A3 SK 12782001A3 SK 12782001 A SK12782001 A SK 12782001A SK 12782001 A3 SK12782001 A3 SK 12782001A3
- Authority
- SK
- Slovakia
- Prior art keywords
- chemokine
- antibody
- construct
- toxin
- chemokine receptor
- Prior art date
Links
- 108010012236 Chemokines Proteins 0.000 title claims abstract description 58
- 102000019034 Chemokines Human genes 0.000 title claims abstract description 57
- 208000023275 Autoimmune disease Diseases 0.000 title claims abstract description 13
- 210000004027 cell Anatomy 0.000 claims abstract description 63
- 108050000299 Chemokine receptor Proteins 0.000 claims abstract description 44
- 102000009410 Chemokine receptor Human genes 0.000 claims abstract description 44
- 210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 27
- 210000001616 monocyte Anatomy 0.000 claims abstract description 24
- 210000002540 macrophage Anatomy 0.000 claims abstract description 13
- 208000026935 allergic disease Diseases 0.000 claims abstract description 7
- 239000003053 toxin Substances 0.000 claims description 38
- 231100000765 toxin Toxicity 0.000 claims description 38
- 230000006378 damage Effects 0.000 claims description 19
- 238000011282 treatment Methods 0.000 claims description 17
- 239000000427 antigen Substances 0.000 claims description 15
- 210000000265 leukocyte Anatomy 0.000 claims description 15
- 239000012636 effector Substances 0.000 claims description 13
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 claims description 12
- 108091007433 antigens Proteins 0.000 claims description 10
- 102000036639 antigens Human genes 0.000 claims description 10
- 238000002360 preparation method Methods 0.000 claims description 10
- 238000000338 in vitro Methods 0.000 claims description 7
- 206010003246 arthritis Diseases 0.000 claims description 5
- 230000001684 chronic effect Effects 0.000 claims description 5
- 239000012634 fragment Substances 0.000 claims description 5
- 230000004927 fusion Effects 0.000 claims description 5
- 238000001727 in vivo Methods 0.000 claims description 5
- 208000018937 joint inflammation Diseases 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 210000004443 dendritic cell Anatomy 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000001363 autoimmune Effects 0.000 claims 2
- 108700011778 CCR5 Proteins 0.000 abstract description 9
- 208000037976 chronic inflammation Diseases 0.000 abstract description 4
- 238000002650 immunosuppressive therapy Methods 0.000 abstract description 3
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 abstract 1
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 abstract 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 abstract 1
- 108700012359 toxins Proteins 0.000 description 30
- 230000000694 effects Effects 0.000 description 13
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 10
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 10
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 10
- 229960004544 cortisone Drugs 0.000 description 10
- 230000009471 action Effects 0.000 description 8
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 7
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 6
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 6
- 208000012659 Joint disease Diseases 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 5
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 5
- 238000004132 cross linking Methods 0.000 description 5
- 230000002757 inflammatory effect Effects 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 210000001503 joint Anatomy 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 102100032367 C-C motif chemokine 5 Human genes 0.000 description 4
- 108010055166 Chemokine CCL5 Proteins 0.000 description 4
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 4
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 4
- 206010023203 Joint destruction Diseases 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 230000003902 lesion Effects 0.000 description 4
- 210000004698 lymphocyte Anatomy 0.000 description 4
- 239000004471 Glycine Substances 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 208000025747 Rheumatic disease Diseases 0.000 description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 230000006020 chronic inflammation Effects 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 108020001507 fusion proteins Proteins 0.000 description 3
- 102000037865 fusion proteins Human genes 0.000 description 3
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 208000027866 inflammatory disease Diseases 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 230000010534 mechanism of action Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
- 102100032366 C-C motif chemokine 7 Human genes 0.000 description 2
- 101710155834 C-C motif chemokine 7 Proteins 0.000 description 2
- 102100034871 C-C motif chemokine 8 Human genes 0.000 description 2
- 101710155833 C-C motif chemokine 8 Proteins 0.000 description 2
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 description 2
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000001147 anti-toxic effect Effects 0.000 description 2
- 239000003435 antirheumatic agent Substances 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000011461 current therapy Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- AEUKDPKXTPNBNY-XEYRWQBLSA-N mcp 2 Chemical compound C([C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)C1=CC=CC=C1 AEUKDPKXTPNBNY-XEYRWQBLSA-N 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 210000001179 synovial fluid Anatomy 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 102000001326 Chemokine CCL4 Human genes 0.000 description 1
- 108010055165 Chemokine CCL4 Proteins 0.000 description 1
- 208000014311 Cushing syndrome Diseases 0.000 description 1
- 102100024746 Dihydrofolate reductase Human genes 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- 101000946926 Homo sapiens C-C chemokine receptor type 5 Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
- 102000012745 Immunoglobulin Subunits Human genes 0.000 description 1
- 108010079585 Immunoglobulin Subunits Proteins 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 101710151805 Mitochondrial intermediate peptidase 1 Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 101150030083 PE38 gene Proteins 0.000 description 1
- 206010036030 Polyarthritis Diseases 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 108700033844 Pseudomonas aeruginosa toxA Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000002579 anti-swelling effect Effects 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 108020001096 dihydrofolate reductase Proteins 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 102000048160 human CCR5 Human genes 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 230000007124 immune defense Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000002637 immunotoxin Effects 0.000 description 1
- 239000002596 immunotoxin Substances 0.000 description 1
- 231100000608 immunotoxin Toxicity 0.000 description 1
- 229940051026 immunotoxin Drugs 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 230000000622 irritating effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- -1 pH adjusters Substances 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 201000009395 primary hyperaldosteronism Diseases 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000012475 sodium chloride buffer Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19910891 | 1999-03-11 | ||
PCT/EP2000/002154 WO2000053633A2 (de) | 1999-03-11 | 2000-03-10 | Antikörper- und chemokinkonstrukte, die gegen ccr5 gerichtet sind, und ihre verwendung in der behandlung von autoimmunkrankheiten |
Publications (1)
Publication Number | Publication Date |
---|---|
SK12782001A3 true SK12782001A3 (sk) | 2002-03-05 |
Family
ID=7900625
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SK1278-2001A SK12782001A3 (sk) | 1999-03-11 | 2000-03-10 | Protilátkové a chemokínové konštrukty a ich použitie pri liečbe autoimunitných chorôb |
Country Status (15)
Country | Link |
---|---|
EP (1) | EP1161456B1 (xx) |
JP (1) | JP2002540771A (xx) |
CN (1) | CN1345336A (xx) |
AT (1) | ATE286074T1 (xx) |
AU (1) | AU4104700A (xx) |
CA (1) | CA2366713A1 (xx) |
CZ (1) | CZ20013270A3 (xx) |
DE (1) | DE50009113D1 (xx) |
ES (1) | ES2233359T3 (xx) |
HU (1) | HUP0200484A2 (xx) |
IL (1) | IL145335A0 (xx) |
NO (1) | NO316916B1 (xx) |
SK (1) | SK12782001A3 (xx) |
TR (1) | TR200102779T2 (xx) |
WO (1) | WO2000053633A2 (xx) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6528625B1 (en) | 1996-10-28 | 2003-03-04 | Millennium Pharmaceuticals, Inc. | Anti-CCR5 antibodies and kits comprising same |
WO2002020615A2 (en) * | 2000-09-08 | 2002-03-14 | Micromet Ag | Antibody and/or chemokine constructs which bind to a chemokine receptor and their use in immunological disorders |
CA2471136A1 (en) * | 2001-12-21 | 2003-07-03 | Micromet Ag | Mono-and dual chemokine/cytokine constructs |
TW200720289A (en) | 2005-04-01 | 2007-06-01 | Hoffmann La Roche | Antibodies against CCR5 and uses thereof |
TW200817438A (en) | 2006-08-17 | 2008-04-16 | Hoffmann La Roche | A conjugate of an antibody against CCR5 and an antifusogenic peptide |
BRPI0715794A2 (pt) | 2006-08-17 | 2013-07-23 | Hoffmann La Roche | conjugado de anticorpo contra ccr5 e peptÍdeo antifusogÊnico |
ATE550355T1 (de) | 2006-09-29 | 2012-04-15 | Hoffmann La Roche | Antikörper gegen ccr5 und ihre verwendung |
CL2008000707A1 (es) | 2007-03-13 | 2008-09-22 | Hoffmann La Roche | Conjugado de polipeptidos antifusogenicos y polipeptidos derivados de la cabeza globular del factor del complemento c1q; composicion farmaceutica que lo comprende; su uso para tratar infecciones viricas; y metodo de produccion. |
CN103429737B (zh) | 2010-11-30 | 2020-07-14 | 中外制药株式会社 | 细胞毒诱导治疗剂 |
US20140271680A1 (en) | 2011-08-12 | 2014-09-18 | Universite Paris-Est Creteil Val De Marne | Methods and pharmaceutical compositions for treatment of pulmonary hypertension |
IL247715B (en) | 2014-04-07 | 2022-07-01 | Chugai Pharmaceutical Co Ltd | Antigen binding molecules that activate the immune system |
EP3144388B1 (en) | 2014-05-13 | 2020-07-01 | Chugai Seiyaku Kabushiki Kaisha | T cell-redirecting antigen-binding molecule for cells having immunosuppression function |
US11649293B2 (en) | 2015-11-18 | 2023-05-16 | Chugai Seiyaku Kabushiki Kaisha | Method for enhancing humoral immune response |
JP6931329B2 (ja) | 2015-11-18 | 2021-09-01 | 中外製薬株式会社 | 免疫抑制機能を有する細胞に対するt細胞リダイレクト抗原結合分子を用いた併用療法 |
US11629196B2 (en) | 2020-04-27 | 2023-04-18 | Incelldx, Inc. | Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6428788B1 (en) * | 1995-03-15 | 2002-08-06 | Penn State University | Compositions and methods for specifically targeting tumors |
US6528625B1 (en) * | 1996-10-28 | 2003-03-04 | Millennium Pharmaceuticals, Inc. | Anti-CCR5 antibodies and kits comprising same |
ZA985542B (en) * | 1997-07-03 | 1999-04-07 | Smithkline Beecham Corp | Substituted benzanilides as CCR5 receptor ligands antiinflammatory agents and antiviral agents |
EP1346731B1 (en) * | 1998-07-22 | 2006-12-06 | Osprey Pharmaceuticals Limited | Conjugates for treating inflammatory disorders and associated tissue damage |
-
2000
- 2000-03-10 ES ES00920490T patent/ES2233359T3/es not_active Expired - Lifetime
- 2000-03-10 SK SK1278-2001A patent/SK12782001A3/sk not_active Application Discontinuation
- 2000-03-10 AT AT00920490T patent/ATE286074T1/de not_active IP Right Cessation
- 2000-03-10 CN CN00804846A patent/CN1345336A/zh active Pending
- 2000-03-10 CZ CZ20013270A patent/CZ20013270A3/cs unknown
- 2000-03-10 WO PCT/EP2000/002154 patent/WO2000053633A2/de active IP Right Grant
- 2000-03-10 IL IL14533500A patent/IL145335A0/xx unknown
- 2000-03-10 AU AU41047/00A patent/AU4104700A/en not_active Abandoned
- 2000-03-10 TR TR2001/02779T patent/TR200102779T2/xx unknown
- 2000-03-10 CA CA002366713A patent/CA2366713A1/en not_active Abandoned
- 2000-03-10 HU HU0200484A patent/HUP0200484A2/hu unknown
- 2000-03-10 DE DE50009113T patent/DE50009113D1/de not_active Expired - Fee Related
- 2000-03-10 EP EP00920490A patent/EP1161456B1/de not_active Expired - Lifetime
- 2000-03-10 JP JP2000604068A patent/JP2002540771A/ja active Pending
-
2001
- 2001-09-06 NO NO20014346A patent/NO316916B1/no unknown
Also Published As
Publication number | Publication date |
---|---|
AU4104700A (en) | 2000-09-28 |
NO20014346D0 (no) | 2001-09-06 |
ATE286074T1 (de) | 2005-01-15 |
CZ20013270A3 (cs) | 2002-02-13 |
HUP0200484A2 (en) | 2002-06-29 |
WO2000053633A3 (de) | 2000-11-16 |
CN1345336A (zh) | 2002-04-17 |
NO316916B1 (no) | 2004-06-21 |
CA2366713A1 (en) | 2000-09-14 |
EP1161456B1 (de) | 2004-12-29 |
NO20014346L (no) | 2001-09-27 |
EP1161456A2 (de) | 2001-12-12 |
DE50009113D1 (de) | 2005-02-03 |
TR200102779T2 (tr) | 2002-03-21 |
IL145335A0 (en) | 2002-06-30 |
JP2002540771A (ja) | 2002-12-03 |
WO2000053633A2 (de) | 2000-09-14 |
ES2233359T3 (es) | 2005-06-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10758556B2 (en) | Anthracycline-based antibody drug conjugates having high in vivo tolerability | |
JP3589459B2 (ja) | 生物応答調節物質の新規な抗体運送システム | |
EP0510949B2 (en) | Cytomodulating conjugates of members of specific binding pairs | |
SK12782001A3 (sk) | Protilátkové a chemokínové konštrukty a ich použitie pri liečbe autoimunitných chorôb | |
IE66223B1 (en) | Recombinant pseudomonas exotoxin construction of an active immunotoxin with low side effects | |
JPH10502544A (ja) | 膜結合cd30抗原の蛋白質分解性開裂及び遊離を防ぐ抗cd30抗体 | |
US20220226441A1 (en) | Immune-cell targeted bispecific chimeric proteins and uses thereof | |
RU2007119989A (ru) | Композиции, слитые конструкции и конъюгаты plad домена | |
AU665763B2 (en) | Interleukin receptor targeted molecules for treatment of inflammatory arthritis | |
TW201801746A (zh) | Cd33抗體藥物結合物與化學治療劑之組合 | |
Liu et al. | Recombinant single‐chain antibody fusion construct targeting human melanoma cells and containing tumor necrosis factor | |
JP2002527403A (ja) | リンホトキシンβ経路の遮断によるウイルス誘導性全身性ショックおよび呼吸窮迫の逆転 | |
JPH0641423B2 (ja) | 細胞毒性薬剤組成物及び細胞毒性薬剤キット | |
US6645494B1 (en) | Anti-CD40L immunotoxins for the treatment of diseases | |
US20220280615A1 (en) | Immune tolerant elastin-like recombinant peptides and methods of use | |
US6613330B1 (en) | Methods and compositions for preventing anti-Gal production in xenograft recipients | |
KR20230019798A (ko) | 항 cd154 항체 및 이의 용도 | |
KR20240024816A (ko) | 우로키나제 유형 플라스미노겐 활성제 수용체 관련 단백질(uparap)을 표적으로 하는 인간화 항체를 포함하는 항체-약물 접합체 | |
TW202241505A (zh) | 抗il-17抗體治療自體免疫性疾病和炎症的方法 | |
JP2005529063A (ja) | 細胞毒性薬剤としての抗体‐アビジン融合タンパク質 | |
Buyuktimkin | Utilizing Antigenic Peptide and Adhesion Molecule Conjugates to Suppress Autoimmune Disease in Animal Models |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC9A | Refused patent application |